Guggenheim assumed coverage of Syndax (SNDX) with a Buy rating and price target of $34, up from $32. The firm views the shares as undervalued given the company’s two commercial drugs and a path to profitability in 2027. Guggenheim believes Syndax’s cash position and Niktimvo profit split alone can justify nearly the entire current share price.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Syndax assumed with a Buy at Guggenheim
- Syndax Pharmaceuticals’ Axatilimab Study: A Potential Breakthrough for IPF Treatment
- 3 Best Stocks to Buy Now, 8/6/2025, According to Top Analysts
- Syndax Pharmaceuticals Faces Ongoing and Emerging Business Risks: A Closer Look at SEC Filings
- Syndax Pharmaceuticals’ Earnings Call Highlights Robust Growth